Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 9—September 2012


Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Allen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas GottliebComments to Author 
Author affiliations: Monash University, Melbourne, Victoria, Australia (A.C. Cheng); Alfred Hospital, Melbourne (A.C. Cheng); Women’s and Children’s Hospital, Adelaide, South Australia, Australia (J. Turnidge); University of Adelaide, Adelaide (J. Turnidge); The Canberra Hospital, Garran, Canberra, Australia (P. Collignon); Australian National University, Canberra (P. Collignon); Princess Alexandra Hospital, Brisbane, Queensland, Australia (D. Looke); University of Queensland, Brisbane (D. Looke); University of South Australia, Adelaide (M. Barton); Concord Hospital, Sydney, New South Wales, Australia (T. Gottlieb); and University of Sydney, Sydney (T. Gottlieb)

Main Article

Table 2

Quinolone antimicrobial drugs available for use in companion animals in Australia under the authority of the Pharmaceutical Benefits Scheme

Drug (date registered) Indication
Difloxacin (2001) Treatment of infections in dogs caused by difloxacin-sensitive organisms
Enrofloxacin (2004) Treatment of urinary and respiratory tract infections, deep pyodermas, wounds, abscesses, and discharging sinuses in dogs caused by enrofloxacin-susceptible bacteria
Orbifloxacin (1999) Treatment of diseases in dogs and cats caused by orbifloxacin-sensitive bacteria
Ibafloxacin (2007) Treatment of urinary tract, respiratory tract, skin, and soft tissue infections in dogs and cats caused by ibafloxacin-sensitive bacteria

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO